ReviewBioMed research international2014
Novel tools for prostate cancer prognosis, diagnosis, and follow-up.
Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Comprehensive Biochemical Insights into Prostate-Specific Antigen: From Biomarker to Functional Mediator in Prostate Cancer Pathophysiology.Anti-cancer agents in medicinal chemistry · 2026Review
- The role of NOP58 in prostate cancer progression through SUMOylation regulation and drug response.Frontiers in pharmacology · 2024Article
- Article
- Article
- Underlying Features of Prostate Cancer-Statistics, Risk Factors, and Emerging Methods for Its Diagnosis.Current oncology (Toronto, Ont.) · 2023Review
- The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.Research square · 2023Article
- Biochemical outcome after curative treatment for localized prostate cancer with external beam radiotherapy: a cross-sectional study.Ecancermedicalscience · 2023Article
- Fibromodulin Gene Variants (Disease markers · 2022Article
- Urinary PCA3 a Superior Diagnostic Biomarker for Prostate Cancer among Ghanaian Men.Disease markers · 2022Article
- Multiplexed Prostate Cancer Companion Diagnostic Devices.Sensors (Basel, Switzerland) · 2021Review
- Myelin and lymphocyte protein 2 regulates cell proliferation and metastasis through the Notch pathway in prostate adenocarcinoma.Translational andrology and urology · 2021Article
- Comprehensive Analysis and Identification of an Immune-Related Gene Signature with Prognostic Value for Prostate Cancer.International journal of general medicine · 2021Article
- MiR-197 Inhibitor Loaded AbCD133@MSNs@GNR Affects the Development of Prostate Cancer Through Targeting ITGAV.Frontiers in cell and developmental biology · 2021Article
- Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-ThroughputInternational journal of molecular sciences · 2020Article
- Article
- Identification of a biomarker panel for improvement of prostate cancer diagnosis by volatile metabolic profiling of urine.British journal of cancer · 2019Article
- Article
- Prognostic value and potential function of splicing events in prostate adenocarcinoma.International journal of oncology · 2018Article
- NMR-based metabolomics studies of human prostate cancer tissue.Metabolomics : Official journal of the Metabolomic Society · 2018Review
- GC-MS-Based Endometabolome Analysis Differentiates Prostate Cancer from Normal Prostate Cells.Metabolites · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific antigen (PSA) is the main diagnostic tool when it comes to prostate cancer but it possesses serious limitations. Therefore, there is an urgent need for more sensitive and specific biomarkers for prostate cancer prognosis and patient follow-up. Recent advances led to the discovery of many novel diagnostic/prognostic techniques and provided us with many worthwhile candidates. This paper briefly reviews the most promising biomarkers with respect to their implementation in screening, early detection, diagnostic confirmation, prognosis, and prediction of therapeutic response or monitoring disease and recurrence; and their use as possible therapeutic targets. This review also examines the possible future directions in the field of prostate cancer marker research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.